Eliminating cancer stem cells (CSCs) is a key issue in eradicating tumor. The streptavidin-granulocyte-macrophage-colony stimulating factor (SA-GM-CSF) surface-modified bladder CSCs vaccine previously developed using our protein-anchor technology could effectively induce specific immune response for eliminating CSCs. However, program death receptor-1 (PD-1)/program death ligand 1 (PD-L1) signaling in tumor microenvironment results in tumor-adaptive immune resistance. Although the CSCs vaccine could increase the number of CD8
Bladder cancer (BCa) is one of the most common malignancies, with high recurrence rate. 1 As we all know, cancer stem cells (CSCs) may play an important role in tumor growth. 2 Eliminating CSCs is a key issue in eradicating tumor. Recurrence of solid tumors may be due to the inability of traditional chemotherapy and radiotherapy to eliminate CSCs. 3 At present, therapeutic vaccines have been extensively used to induce endogenous tumor-reactive T cells. 4, 5 We have developed a technology that immobilizes streptavidin (SA)-tagged bioactive cytokines on the biotinylated tumor cell surface to prepare tumor cell vaccines. This type of therapeutic vaccine not only retains the biological activity of cytokines but also maintains high local cytokine concentrations and reduces metabolism rates and side effects. 6 We previously developed granulocyte-macrophage-colony stimulating factor (GM-CSF) surface-modified CSCs vaccine to induce specific immune response for eliminating CSCs. [6] [7] [8] GM-CSF is a cytokine that promotes the growth and maturation of DCs and initiates the immune response. 9 Although the therapeutic CSCs vaccine could significantly enhance dendritic cells (DCs) activation, tumor-specific cytotoxic Tlymphocyte activity, and antitumor responses in vivo, this effect is usually restricted to the early stages of tumor growth. Immunity decays with tumor growth, concurrent with the establishment of a tumor microenvironment (TME) in which cancer cells are embedded in a suppressive tumor stroma. The limited success of earlier therapeutic vaccination approaches is likely due to vaccine-generated T cells becoming dysfunctional once they have infiltrated long-established suppressive tumors. A major advance in clinical immunotherapy is the blockade of inhibitory immune receptors and their ligands, collectively termed immune checkpoints. 10 Specifically, the clinical efficacy blocking program death receptor-1 (PD-1)/program death ligand 1 (PD-L1) was recently shown in several advanced malignancies.
PD-1/PD-L1 signaling constitutes a major tolerance mechanism. 13 PD-L1 is expressed by tumor cells, antigenpresenting cells, B cells and parenchymal cells. 14 PD-1 is mainly expressed on activated T cells. 10 PD-L1/PD-1 interaction results in T-cell anergy or death, thereby blunting antitumor immune responses and promoting tumor growth. 15 Expression of PD-L1 has been detected in BCa. 16 Despite some reports correlating PD-L1 expression with a poorer prognosis, the role of this pathway in BCa is not fully understood. 17 Anti-PD-1 antibody has been shown to be effective in treating BCa by rescuing dysfunctional T cells. However, anti-PD-1 monotherapy did not induce a natural infiltration of effector immune cells into the TME to produce a tumorspecific immune response 18, 19 that limits the therapeutic effect. A potential strategy for activating effector T-cells trafficking into the TME is vaccine-based immunotherapy. Therefore, we speculated that a combination therapy of CSCs vaccine and PD-1 blockade may hold greater potential for eliciting an immune response for eliminating CSCs. In our study, we first reported the efficacy of a combination therapy involving the SA-GM-CSF surface-modified bladder CSCs vaccine and PD-1 blockade in a mouse model of BCa.
Material and Methods

Animals and cells
The mouse BCa cell line MB49 (a carcinogen-induced transitional cell carcinoma derived from C57BL male mice) and the prostate cancer cell line RM-1 (derived from the spontaneous prostate tumors that occur in the Zipras/myc-9-infected C57BL/6 mouse prostate reconstitution model) were stored at our research institution. C57BL/6 mice and nude mice were purchased from the experimental animal center at Southern Medical University (Guangzhou, China). All procedures were carried out in accordance with relevant laws and institutional guidelines (ethical number: L2016152). The MB49 cells and RM-1 cells were cultured in RPMI1640 containing 10% fetal bovine serum, 1% penicillin/streptomycin and 0.1% sodium pyruvate in a 5% CO 2 humidified incubator. MycoplasmaOUT (Genloci, Nanjing, China) was used to protect the cells against mycoplasma contamination. The cell lines used in our study have been authenticated and tested for mycoplasma contamination. SA-GM-CSF fusion protein and SA-green fluorescent protein (GFP) fusion protein were prepared by our laboratory.
Establishment of MCSCs
Our previous study showed that the optimal serum-free culture medium (SFM) consisted of RPMI1640, basic fibroblast growth factor (20 ng/mL), epidermal growth factor (20 ng/ mL), B-27 serum-free supplement (20 lL/mL), leukemia inhibitory factor (20 ng/mL) and bovine serum albumin (4 lg/mL). 6 For the limited dilution method, MB49 cells were digested with accutase-enzyme cell detachment medium (eBioscience, San Diego, California) and were adjusted to a density of 5 cells/mL. Two hundred microliters of cell suspension was then plated into 96-well plates, and single cells were marked and observed daily. Most cells were unable to proliferate in SFM, only a small percentage of cells generated clone spheres. These single cells extracted from MB49 cells were called MCSCs. Quantitative polymerase chain reaction (qPCR) was used to evaluate the expression of CD44, CD133, OCT4 and NANOG. Total RNA was extracted using the Arcturus PicoPure RNA isolation kit (Biosciences, Carlsbad, New Mexico). RNA quality was verified by the Bioanalyzer RNA Pico Chip (Agilent Technologies, Santa Clara, California). Two micrograms of total RNA were reverse transcribed with Superscript III (Invitrogen, Grand Island, New York). cDNA was amplified with SYBR green PCR master mix (Bio-Rad, Hercules, California) on a 7500 real time PCR system (AB Applied Biosystems, Singapore). Cycling conditions were 958C for 10 sec (denaturation) and 608C for 60 sec (annealing and extension). Normalization and fold changes were calculated using the DDCt method, and GAPDH was used as negative control.
Expression of MCSCs markers
Tumorigenic ability and chemotherapy resistance
Nude mice (4 weeks) were maintained and treated under specific, pathogen-free conditions. A total of 1 3 10 4 MCSCs or 1 3 10 6 MB49 cells were injected subcutaneously into the hind leg of nude mice. Tumor xenograft formation was observed for 45 days, and the volume of the tumor was measured. MCSCs were adjusted to 1 3 10 4 per well in a 96-well plate. After 24 hr, mitomycin (Sigma, Saint Louis, Missouri), cisplatin (Sigma), paclitaxel (Sigma) or doxorubicin (Sigma) was added with different concentrations respectively, and cells were treated for a subsequent 96 hr. Then CCK-8 reagent was added to each well, and the absorbance values were measured after 4 hr of incubation. Cell viability was expressed as the percentage of absorbance values of the treated wells related to the absorbance of the untreated control wells.
MCSCs vaccine preparation
Our previous study showed that 30% ethanol (v/v) could completely inactivate tumor cells and keep cell shape and size intact. 20 Ethanol-fixed MCSCs (1 3 10 6 cells/mL) were incubated with 10 mM fresh EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, Illinois) for 1 hr at room temperature and washed three times with PBS. The biotinylated cells were incubated with SA-GM-CSF at 100 ng/10 6 cells for 1 hr and washed three times with PBS. The presence of SA-GM-CSF on the surface of MCSCs was assayed by FCM.
Biological activity of SA-GM-CSF-modified MCSCs vaccine
The MCSCs vaccine was lysed by three cycles of freezing and thawing. Membrane fractions were harvested by centrifugation at 15,000g for 5 min and resuspended in complete medium. The bioactivity of SA-GM-CSF immobilized on the surface of MCSCs was assessed by bone marrow cell (BMC) proliferation, and SA-GFP was used as a negative control. Aliquots of cell membrane fractions were added to 1 3 10 4 BMCs in each well and then incubated for 3 days in a 5% CO 2 humidified incubator. Then, 20 mL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) was added to each well for 4 hr. The reaction was terminated by adding 200 mL dimethyl sulfoxide to each well, and the optical density (OD) at 570 nm was read on a microplate reader.
Immunotherapy with SA-GM-CSF-modified MCSCs vaccine
A total of 1 3 10 5 MCSCs suspended in 100 mL of PBS were injected subcutaneously into the hind leg of C57BL mice (6-8 weeks) to establish a subcutaneous model. Mice were then randomly divided into four groups (PBS, ethanol-fixed MCSCs, SA-GM-CSF or anchored-GM-CSF MCSCs vaccine). For the anchored-GM-CSF group, the mice were injected subcutaneously with GM-CSF-modified MCSCs vaccine (1 3 10 5 cells/100 lL PBS) on days 0, 4, 8 and 12 after tumor injection. For the other three control groups, the mice were injected subcutaneously with PBS (100 lL), ethanol-fixed MCSCs (1 3 10 5 cells/100 lL PBS) or SA-GM-CSF (1 ng/ 100 lL PBS) on days 0, 4, 8 and 12 after tumor injection.
Flow cytometry analysis of dendritic cells after SA-GM-CSF-modified MCSCs vaccine therapy
To evaluate whether the SA-GM-CSF-modified MCSCs vaccine could induce the maturation of DCs, splenocytes were isolated from each experimental group on Day 19 after tumor injection, and red blood cells were lysed by FCM Lysing Solution (Multisciences Biotech, Hangzhou, China) for 10 min. The splenocytes were washed with PBS 1 1% BSA and then stained with FITC-labeled anti-mCD11c and PE-labeled anti-mCD80 antibodies (Biolegend, San Diego, California) for 30 min at room temperature. Double positive cells considered to be mature DCs were measured by FCM.
Expression of PD-L1 and PD-1
1
CD8
1 T cells infiltrated in TME after SA-GM-CSF-modified MCSCs vaccine therapy
Immunofluorescence was performed to directly observe the degree of PD- 1 T cells and the expression of PD-L1 in the TME were then observed through a fluorescence microscope (Nikon, Eclipse E800).
Combination therapy with SA-GM-CSF-modified MCSCs vaccine and PD-1 blockade
A total of 1 3 10 5 MCSCs suspended in 100 mL of PBS were injected subcutaneously into the hind leg of C57BL mice (6-8 weeks) to establish a subcutaneous model. Mice were then randomly divided into four groups (IgG, anti-mPD-1, anchored-GM-CSF 1 IgG and anchored-GM-CSF 1 antimPD-1 group [combined group]). For the combined group, the mice were injected subcutaneously with SA-GM-CSFmodified MCSCs vaccine (1 3 10 5 cells/100 lL PBS) and injected i.p. with anti-mPD-1 monoclonal antibody (100 mg) on days 0, 4, 8 and 12 after tumor injection. For the other three control groups, the mice were injected subcutaneously or injected i.p. with IgG (100 mg), anti-PD-1 monoclonal antibody (100 mg) or SA-GM-CSF-modified MCSCs vaccine (1 3 10 5 cells/100 lL PBS) 1 IgG (100 mg) on days 0, 4, 8 and 12 after tumor injection.
Specific immune response
On Day 19 after tumor challenge, splenocytes were isolated from the mice of each group and stimulated by inactivated MCSCs plus 20 U/mL of hIL-2 (R&D Systems) for 5 days. These splenocytes served as effector cells and were adjusted to 1 3 10 5 cells/mL in the RPMI-1640 medium. MCSCs served as target cells and were adjusted to a density of 1 3 10 4 /mL. Both were added to a 96-well plate at the desired E:T ratios. After 4 hr of incubation, the supernatant was collected and the LDH activity was measured by the CytoTox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI) to assess the cytotoxicity of tumor-specific cytotoxic T lymphocytes (CTL). The percentage of cytotoxicity was calculated as follows: CTL 5 (experimental -effector spontaneous -target spontaneous)/(target maximum -target spontaneous) 3 100%.
To confirm the specific immune response in vivo, the surviving mice in the combined group were injected subcutaneously with 1 3 10 5 MCSCs (in the left hind leg) and RM-1 cells (in the right hind leg) on Day 45 after therapeutic vaccination.
Flow cytometry analysis of T-cell subsets after combination therapy with SA-GM-CSF-modified MCSCs vaccine and PD-1 blockade
To determine the effect of the therapeutic vaccine together with PD-1 blockade on different T-cell subsets, 100 mL peripheral blood was collected from each experimental group on Day 19 after tumor injection. To enumerate the CD4 1 and CD8 1 T-cell subsets, cells were stained with PE-labeled anti-mCD4 and FITC-labeled anti-mCD8 (eBscience). To enumerate the IFN-
, PD-1 1 CD8 1 and CD4 1 Foxp3 1 T-cell subsets, cells were first stained with FITC-labeled anti-mCD8 or FITClabeled anti-mCD4 (Biolegend), then fixed or permeabilized before they were stained with PE-labeled anti-IFN-g, PElabeled anti-PD-1 or PE-labeled anti-FoxP3 antibody (Biolegend). T-cell subsets were measured by FCM (Becton Dickinson).
Immunohistochemistry and immunofluorescence analyses for tumor-infiltrating T lymphocytes
On Day 19 after tumor injection, tumor tissues were collected from each experiment group and embedded in freezing medium. The frozen sections were fixed in cold acetone for 15 min and incubated with anti-mCD4 (Bioworld, New Brunswick, NJ) or anti-mCD8 (Epitomics, Burlingame, California) for 1 hr. The anti-mCD4 or anti-mCD8 antibody was then visualized using the anti-rat Ig SABC kit (spring, Pleasanton, California) and counter stained with hematoxylin and eosin. In addition, immunofluorescence was performed to detect the degree of PD-1 1 CD8 1 T-cell infiltration in tumor tissues. The frozen sections were incubated with rabbit antimouse PD-1 (eBioscience) 1 rat anti-mouse CD8 (eBioscience) for 60 min. Slides were washed with TBST for 5 min three times, and secondary Abs (Alexa Fluor 647-labeled goat anti-rabbit Abs [red fluorescence] and Alexa Fluor 488-labeled goat anti-rat Abs [green fluorescence]; eBioscience) were added for 30 min. Slides were washed three times with TBST for 10 min and mounted with a Vectashield Dapi containing kit. PD-1
1
CD8
1 T cells in the TME were then observed through a fluorescence microscope.
Determination of IFN-c, IL-4, IL-10 or IL-12 concentrations by ELISA
On Day 19 after tumor injection, 100 mL peripheral blood was collected from each experiment group and congealed at room temperature for 20 min. The supernatant was then harvested by centrifugation at 3000 r.p.m. for 5 min. The concentrations of IFN-g, IL-4, IL-10 or IL-12 were measured by ELISA (R&D Systems, Minneapolis, MN).
Upregulation of PD-L1 expression induced by IFN-c
To determine the role of IFN-g in upregulating PD-L1 expression, MCSCs were cultured in the presence of IFN-g (500 IU/mL) for 72 hr. Cells were then stained with PElabeled anti-mPD-L1, and the mean fluorescence intensity was measured by FCM.
Effect of PD-1 blockade on tumor-specific cytotoxic activities
Splenocytes were isolated from the surviving mice of the combined group on Day 19 after tumor challenge. The PD-1
1
CD8
1 T-cell subset was then sorted by magnetic beads. The PD-1
1
CD8
1 T cells served as effector cells and were adjusted to 1 3 10 5 cells/mL in the RPMI-1640 medium. The MCSCs cultured with IFN-g for 72 hr served as target cells and were adjusted to a density of 1 3 10 4 /mL. AntimPD-1 antibody (eBscience) was used to block PD-1/PD-L1 with isotype IgG antibody as a control. The CTL was assessed by the CytoTox 96 nonradioactive cytotoxicity assay (Promega).
Statistics
Statistical analyses of FACS, ELISA, immunohistochemistry and immunofluorescence data were performed using one-way ANOVA. The differences in tumor volume between groups were compared using repeated measures design. All analyses were performed using SPSS (version 19.0), with p < 0.05 considered indicative of statistical significance.
Results
Characterizations of MCSCs
MCSCs were extracted from MB49 cells by limited dilution method. FCM analysis was then used to detect the markers on the surface of CSCs. The proportion of CD44 1 cells in MB49 cells was higher than in MCSCs, and MCSCs events collected were smaller on account of the difficulty in proliferation. However, more CD133
1 CD44 1 cells were detected in MCSCs than that in MB49 cells (Fig. 1a) . In addition, qPCR was used to evaluate the expression of several markers. The results showed that the relative levels of CD133, OCT4 and NANOG mRNA were higher in MCSCs when compared to MB49 cells, but the level of CD44 was higher in MB49 cells (Fig. 1b) .
To confirm the tumorigenic ability in vivo, a total of 1 3 10 5 MCSCs or 1 3 10 6 MB49 cells were injected subcutaneously into nude mice. The tumor volume in MCSCs group was significantly bigger than that in MB49 cells group (p < 0.05), suggesting that MCSCs possessed strong tumorigenic ability in vivo (Fig. 1c) . In addition, to confirm the chemotherapy resistance, MCSCs were cultured with several anticancer drugs. Compared to MB49 cells, MCSCs showed lower susceptibility to all four traditional anticancer agents (mitomycin, cisplatin, paclitaxel and doxorubicin; Fig. 1d ).
Immobilization and biological activity of SA-GM-CSF Through our protein-anchor technology, the SA-tagged bioactive cytokines can be immobilized on the biotinylated tumor cell surface. FCM results showed that SA-GM-CSF could be efficiently anchored on the surface of ethanol-fixed MCSCs (Fig. 2a) . In addition, the bioactivity of SA-GM-CSF immobilized on the surface of MCSCs was assessed by BMC proliferation, with SA-GFP as a negative control. The results showed that SA-GM-CSF fusion protein anchored on the biotinylated surface of MCSCs still retained their bioactivity in a dosage-dependent manner (Fig. 2b) . DCs in MCSCs vaccine group were the highest among four groups (Fig. 3a) .
GM-CSF-modified
However, the therapeutic CSCs vaccine enhanced the expression of PD-L1 and infiltration of PD-1 1 CD8
1
T cells in TME at the same time. To confirm the existence of PD-1/ PD-L1 signaling in TME, the tumor specimens were collected from the mice treated with PBS, ethanol-fixed MCSCs, SA-GM-CSF or anchored-GM-CSF MCSCs vaccine on Day 19 after tumor challenge. Immunofluorescence was performed to directly observe the degree of PD-1
CD8
1 T-cell infiltration and the expression of PD-L1 in tumor tissues. As shown in Figure 3b , the MCSCs vaccine significantly upregulated the expression of PD-L1 (red fluorescence) in the TME. Although more CD8 
PD-1 blockade enhanced therapeutic efficacy of GM-CSFmodified MCSCs vaccine
We examined whether blocking PD-1 could augment the antitumor activity of the MCSCs vaccine in a subcutaneous model of BCa. The study contained four groups (IgG, antimPD-1, anchored-GM-CSF 1 IgG and anchored-GM-CSF 1 anti-mPD-1 group [combined group]). For the combined group, the mice were injected subcutaneously with 1 3 10 5 SA-GM-CSF-modified MCSCs vaccine and injected i.p.
with 100 mg of anti-mPD-1 antibody. According to the results, both the MCSCs vaccine alone and PD-1 blockade alone modestly slowed tumor growth, but they could not thoroughly eradicate tumors. The combination treatment of the MCSCS vaccine and PD-1 blockade produced the best antitumor response in vivo, which significantly delayed tumor growth (p < 0.05; Fig. 4a ) and reduced wet tumor weight (p < 0.05; Fig. 4b ). On Day 45 after tumor injection, the proportion of mice that were tumor-free in IgG, anti-mPD-1, anchored-GM-CSF 1 IgG and anchored-GM-CSF 1 antimPD-1 groups were 0, 8.9 6 10.2%, 33.3 6 6.7% and 60.0 6 13.3%, respectively (p < 0.05).
To assess the CTL induced by combination therapy, the splenocytes served as effector cells and MCSCs served as target cells. The results of CTL assay showed that PD-1 blockade could significantly enhance the tumor-specific cytotoxic activities of the MCSCs vaccine relative to those of the MCSCs vaccine monotherapy (p < 0.05; Fig. 4c ). To confirm that PD-1 blockade combined with the MCSCs vaccine could induce a tumor-specific immune response in vivo, the surviving mice in the combined group were injected subcutaneously with a second set of MCSCs, with RM-1 cells as a control. The results showed that the combination therapy could effectively protect the mice against the second set of MCSCs but not the RM-1 cells challenge (Fig. 4d) , which demonstrated that the combination therapy could effectively induce tumorspecific T-cell immunity.
T-cell subsets after combination therapy with GM-CSFmodified MCSCs vaccine and PD-1 blockade
To investigated the effect of single immunotherapy or combined treatment on different T-cell subsets, peripheral blood was collected from each experimental group on Day 19 after tumor injection. FCM was used to detect the T-cell subsets. As shown in were the highest among the four groups (p < 0.05; Fig. 5a ).
To further understand the significance of PD-1 blockade in regulating immune response, the proportions of the IFN- The proliferative activity of membraneconjugated GM-CSF on BMCs was assessed, with SA-GFP as a negative control. All the experiments were replicated at least three times (*p < 0.05 and **p < 0.01).
, PD-1 1 CD8 1 and CD4
1
Foxp3
1 T-cell subsets were also measured (Fig. 5b) . The results showed that the combined group had the highest proportion of IFN-g 1 CD8
1
T cells among the four groups, suggesting that the MCSCs vaccine combined with PD-1 blockade enhanced the activation of IFN-g production in CD8
1 T cells. Anti-PD-1 monotherapy significantly increased the percentage of CD4 1 Foxp3 1 T cells (Tregs), but adding the MCSCs vaccine to PD-1 blockade decreased the percentage of Tregs. Similar to the results observed in the TME, although the combined group had more CD8 1 T cells than the other groups, the proportions of PD-1 1 CD8 1 T cells also increased. Therefore, the CD8 1 Tcell response generated by the GM-CSF-modified MCSCs vaccine required enhancement by blocking PD-1. In addition, to examine whether combination therapy could increase the tumor-infiltrating T cells, tumor specimens were collected from mice of each group. Immunohistochemistry and immunofluorescence were performed to directly observe the degree of CD4
, CD8
1 and PD-1 1 CD8 1 T-cell infiltration in the tumor tissues. The results showed that more CD4 1 and CD8 1 T cells infiltrated the tumor tissues in the combined group than in the other groups (Fig. 5d) . Although the combination therapy increased the total number of CD8 1 T-cell in TME, the number of PD-1
1
CD8
1 T cell also increased. So PD-1 blockade is necessary in the treatment with GM-CSFmodified MCSCs vaccine.
Measurements of IFN-c, IL-4, IL-10 or IL-12 in serum
Certain cytokines in vivo may reflect immune status. IFN-g is considered to be the most potent in inhibiting tumor cell growth. 21 IL-12 plays an important role in the immune response mediated by Th1 cells. 22 IL-10 is a key factor of immunosuppression. 23 IL-4 is an important factor of humoral immunity. 24 To investigated the immune status in 
CD8
1 T cells. The results of statistical analyses showed significant differences in the number of positive cells (n 5 15). All the experiments were replicated at least three times (*p < 0.05 and **p < 0.01).
vivo after treating with single immunotherapy or combination therapy, the supernatant of peripheral blood from each group was collected. As shown in Figure 6a , consistent with the results of the IFN-g 1 CD8 1 T-cell analysis, the serum of the combined group displayed a higher concentration of IFN-g than either the MCSCs vaccine or PD-1 blockade alone. Moreover, the combined group showed the highest concentration of IL-12 (p < 0.05) but lowest concentration of IL-10 among the four groups (p < 0.05). No significant differences in the concentration of IL-4 were observed among the four groups (p > 0.05).
IFN-c upregulated PD-L1 expression of tumor cells
To better study the role of IFN-g in regulating the PD-L1 expression of tumor cells, MCSCs were cultured with IFN-g for 72 hr. FCM analysis was used to detect the PD-L1 expression of tumor cells. The results showed that the PD-L1 expression of tumor cells was significantly upregulated (p < 0.05; Fig. 6b ), supporting the important role of IFN-g in PD-L1 expression.
PD-1 blockade enhanced tumor-specific cytotoxic activities
To test whether PD-1 blockade could augment antitumor activity in vitro, PD-1 1 CD8 1 T cells isolated from the mice treated with the combined immunotherapy served as effector cells and the MCSCs that expressed PD-L1 served as target cells. Both effector cells and target cells were cultured with or without anti-PD-1 antibody. The results of CTL assay showed that the tumor-specific cytotoxic activities could be significantly enhanced by PD-1 blockade based on the presence of an effective immune response (Fig. 6c) . 
CD8
1 T-cell-infiltrating tumor tissues from mice of each group (n 5 15). All the experiments were replicated at least three times (*p < 0.05 and **p < 0.01).
Tumor Immunology and Microenvironment
Discussion
To our knowledge, the present study is the first report of a combination therapy involving the SA-GM-CSF surfacemodified bladder CSCs vaccine and PD-1 blockade targeting a characterized population of CSCs in BCa. Through our protein-anchor platform, the proposed MCSCs vaccine not only contained all of the tumor-associated antigens but also maintained the activity of cytokines to enhance the immunogenicity of the vaccine. Our previous study demonstrated that the GM-CSF-modified MCSCs vaccine could significantly promote the uptake of tumor-associated antigens by the immune system and enhance the immunogenicity of tumor cells, tumor-specific CTL activity, and in vivo antitumor responses. [6] [7] [8] The results of our study also showed that more mature DCs were detected in the spleen of mice treated with the MCSCs vaccine. However, although this vaccination approach induced unprecedentedly strong CD8
1 T-cell responses and CD4 1 T-cell responses, this effect was usually restricted to the early stages of tumor growth. The TME contains a strong immunosuppressive network that limits the antitumor immune response. 25 Currently, tumor-adaptive immune resistance and checkpoint blockade are under intense investigation. The antitumor activity of the vaccine was enhanced when combined with antibodies blocking PD-1 or PD-L1. 26 This approach may also be advantageous for targeting BCa. In the present study, we tested whether it is possible to optimize our strongly immunogenic but moderately efficacious vaccination platform by intervening the PD-1/PD-L1 axis. PD-1/PD-L1 interactions inhibit the functions and proliferation of activated T lymphocytes. 27 Interruption of the PD-1/PD-L1 pathway is currently being investigated and has shown promising results in several carcinomas. 28, 29 Upregulation of PD-L1 in the TME predicts poor survival in patients with cancer. 30, 31 Some studies have reported the therapeutic efficacy of anti-PD-1 monotherapy against BCa in mouse models. 26, 32 However, PD-1 blockade alone has no significant antitumor effect, likely because PD-1 pathway blockade does not induce a sufficiently strong antitumor response to delay BCa growth. 33 In addition, anti-PD-1 monotherapy increased the percentage of CD4 The immune tolerance mediated by PD-1/PD-L1 signaling exists in the TME after vaccine-based cancer immunotherapy. In our study, we showed that PD-L1 expression in the TME was significantly upregulated in murine BCa after treating with the GM-CSF-modified MCSCs vaccine. The GM-CSF-modified MCSCs vaccine treatment could induce the infiltration of more CD8 1 T cells into tumor tissues, but a part of CD8
1
T cells expressed high level PD-1. The tumor-specific immunity could not thoroughly eradicate tumors, which supports the notion that adaptive resistance exists within the TME of BCa. Treatment with repeated doses of vaccine does not provide additional therapeutic benefit because the functions of tumorinfiltrating T cells might be suppressed through PD-1/PD-L1 interactions. 35 As confirmed by a published study, IFN-g is a known mediator of PD-L1 expression in cancer cell lines. 36 In vitro study, we also showed that PD-L1 expression on tumor 
CD8
1 T cells isolated from the mice treated with the combined immunotherapy served as effector cells, and the MCSCs expressing PD-L1 served as target cells. CTL was performed with or without anti-PD-1 antibody. All the experiments were replicated at least three times (*p < 0.05 and **p < 0.01).
cells was upregulated in the presence of IFN-g. Tumor-infiltrating T cells could produce IFN-g, which might be the reason for the upregulation of PD-L1 expression in TME after cancer vaccine therapy. According to published studies, PD-L1 is mainly expressed by tumor cells, antigen-presenting cells, B cells and parenchymal cells.
14 No matter what type of cell expressing PD-L1, these findings suggest that upregulation of PD-L1 expression in TME infiltrated IFN-g-producing CD8
1 T cells subsequently results in adaptive resistance. PD-1 blockade appeared to play a vital role in the antitumor immunity induced by the combination therapy. Therefore, an effective immunotherapy should combine checkpoint blockade with a driver of tumor-specific immunity. The most straightforward approach to accomplish this would be to combine a cancer vaccine that can increase tumor-specific TH1 IFN-g-secreting lymphocytes with PD-1/PD-L1 blockade. Our study demonstrates that PD-1 blockade could overcome this vaccineinduced adaptive resistance to produce a stronger immune response against MCSCs, most likely accounting for the improvement in cure rate observed in these mice.
Combined therapy of MCSC vaccine and PD-1 blockade effectively induced specific immune response for eliminating MCSCs. On Day 45 after tumor injection, 60% of mice in combined group were tumor free. Comparing with the MCSC vaccine or anti-PD-1 blocker monotherapy, the improvement of cure rate in the combined group benefited from the synergistic effect of the MCSC vaccine and PD-1 blockade. However, although combined therapy greatly inhibited the tumor growth and completely eliminated tumor in majority of mice, the tumor in a few mice could not be completely eradicated. More experiments should be performed to examine the characteristics of cancer cells that could not be eliminated. CSCs have a strong ability to proliferate and differentiate. The differentiated cancer cells might be the reason for failing to completely eradicate tumor in a few mice. A therapeutic strategy for adding chemotherapy or radiotherapy targeting the differentiated cancer cells may be suitable for these mice.
In addition, a number of factors potentially contribute to the relatively inefficient control of neoplastic growth by vaccines. 37 The immune evasion mechanisms of a established tumor are multifactorial, and we have not addressed the role of stromal tissue or myeloid cells in their response to the combination of the GM-CSF-modified MCSCs vaccine and PD-1 blockade. Moreover, the addition of other immune checkpoint blockades to further improve the cure rates in our system remains an open issue. Addition of anti-CTLA-4 with anti-PD-1 to vaccines was reported to be effective in inducing the partial regression of established colon and ovarian carcinoma models. 38 Various combinations of translatable blocking checkpoint molecules (anti-CTLA-4, anti-LAG3 and anti-TIM3) can be optimized to treat BCa in the future.
In sum, the GM-CSF-modified MCSCs vaccine significantly augments the priming of tumor-specific T cells and is an excellent candidate to serve as a component in a combination therapy with PD-1 blockade or other forms of immune checkpoint blockade in cancer patients. Our study further supports the notion that PD-1 blockade combined with the GM-CSF-modified MCSCs vaccine could induce better antitumor immunity in a subcutaneous model of BCa than the vaccine or PD-1 blockade alone. Our future studies will continue to explore the exact immune mechanism and the effect of combinations with other immune checkpoint blockades. These findings may provide an experimental basis for applying this type of combination therapy to the treatment of human BCa.
